What is the SYNAPSE-CMT Clinical Trial?
CMTA-STAR Alliance Partner NMD Pharma has recently started screening and enrolling patients in the SYNAPSE-CMT Phase II trial. This trial aims to evaluate the safety, tolerability, and potential effectiveness of an investigational medication, NMD670.
NMD670 is a novel medication that works by enhancing communication between nerves and muscles, a common issue for people living with CMT. The hope is that this treatment will improve your strength, endurance, and overall daily functioning. By joining the study, you’ll play a critical role in determining whether this therapy could help others with CMT in the future.
NextGen Precision Health
Columbia, Missouri
Principal Investigator: W. David Arnold, MD
Contact: Neetha Gali
Email: ngdcd@health.missouri.edu
Phone: (573) 882-3065
National Neuromuscular Research Institute
Austin, Texas
Principal Investigator: Yessar Hussain, MD
Contact: Stephanie Gonsoulin, RN, BSN
Email: stephanie@austinneuromuscle.com
Phone: (512) 920-0140 x210
Ohio State University Department of Neurology Division of Neuromuscular Diseases
Columbus, Ohio
Principal Investigator: Bakri Elsheikh, MD
Contact: Lischele Watkins, MACPR
Email: janesmith@example.com
Address: 2006 Kenny Rd, Columbus, OH 43221
Office: 614-293-1737
Fax: 614-366-8933
Providence Medical Research Center
Spokane, WA
Principal Investigator: Gregory Carter, MD, MS
Contact: Shane White
Email: shane.white@providence.org
Address: 105 W 8th Avenue, Suite 532C, Spokane, WA 99204
Office: 509-474-3724
Fax: 509-474-4338
Columbia University Medical Center Neurological Institute
New York, NY
Principal Investigator: Thomas Brannagan, MD
Contact: Raisy Fayerman
Email: rf2632@cumc.columbia.edu
Address: 710 West 168th St., 2nd Floor, Suite 204, New York, NY 10032
Office: 212-305-6035
Massachusetts General Hospital
Boston, MA
Principal Investigator: Reza Seyedsadjadi, MD
Email: rseyedsadjadi@mgh.harvard.edu
Office: 919-280-5582
University of Rochester Neuromuscular Disease Center
Rochester, NY
Principal Investigator: David Herrmann, MD
Contact: Beth Wood
Email: ElizabethP_Wood@urmc.rochester.edu
Address: 601 Elmwood Avenue, Box 673, Rochester, NY 14642
Office: 585-276-6248
Fax: 585-276-2492
Other locations, including those in New York, Boston, Kansas, Ohio, and Washington will be opening soon. Most sites are offering to share their contact information to interested patients/families, but some may not be willing to share that publicly. If the contact information is available on Clinicaltrials.gov, that means they have agreed to share publicly. If a site has not offered to share publicly, interested parties can contact us at NMD Pharma with questions and we can help facilitate answers to questions and connection to sites. Email at contact@nmdpharma.com
CMTA-STAR’s Role in Advancing Research
As the global leader in driving progress for all types of CMT, CMTA is proud to support CMTA-STAR Alliance Partner NMD Pharma. Together, we are committed to patient-centered research prioritizing real-world impacts for those living with CMT. Your participation in the SYNAPSE-CMT trial exemplifies the power of collaboration between researchers, clinicians, and the patient community.
How to Participate
If you meet the eligibility criteria and wish to take part in the SYNAPSE-CMT Phase II clinical trial:
- Contact NMD Pharma at contact@nmdpharma.com.
- Visit SYNAPSE-CMT trial for official study information.
Register with Patients as Partners in Research Today
Not yet registered with Patients as Partners in Research but wish to be informed about more opportunities like the SYNAPSE-CMT trial? Click the button below to register today! Registering today ensures you will be the first to hear when NMD Pharma announces new trial locations. Registering also ensures you are updated on all the latest news and developments in CMT research. Registration is free and secure, and all who have CMT are invited to register.
Create Your Patients as Partners in Research Profile
Published on: December 10, 2024
Last Updated: January 10, 2025